Itoco

Dorzolamide, the active ingredient in Itoco, is a carbonic anhydrase inhibitor presented as a topical ophthalmic solution for ocular (topical) use. It lowers intra‑ocular pressure and is employed in the management of glaucoma and ocular hypertension, particularly in patients with primary open‑angle glaucoma, helping to preserve visual function.

GNH USA supplies Itoco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, providing reliable access to quality‑assured ophthalmic medicines for diverse healthcare markets and supporting patient care.

Dorzolamide is used to reduce intra‑ocular pressure in glaucoma‑related conditions.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic nerve damage. - Ocular hypertension: reduces elevated eye pressure to decrease risk of progression to glaucoma. - Secondary glaucoma: used as adjunct therapy when other treatments are insufficient to control pressure.

Adverse reactions may occur with topical dorzolamide use.

Common Side Effects: - Eye burning or stinging - Transient blurred vision - Metallic taste alteration - Redness of the eye

Serious or Rare Side Effects: - Severe allergic reaction, including angioedema or anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing dorzolamide, consider the following precautions.

- Assess intra‑ocular pressure before initiating: monitor regularly during therapy. - Avoid in patients with sulfonamide hypersensitivity: consider alternative treatment. - Use with caution in severe renal impairment: adjust therapy as needed. - Do not combine with other carbonic anhydrase inhibitors without supervision: risk of additive IOP lowering. - Discontinue if severe ocular irritation occurs: seek medical advice promptly. - Store at room temperature: keep in original container, protect from light and moisture.

Dorzolamide may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): increased risk of systemic acidosis. - Topical beta‑blockers (e.g., timolol): additive systemic side effects.

Moderate Interactions (Monitor Closely): - Topical prostaglandin analogs: may enhance intra‑ocular pressure reduction, monitor pressure. - Topical corticosteroids: may reduce dorzolamide efficacy. - Systemic sulfonamides: potential hypersensitivity cross‑reaction.